Abstract: Objective To investigate the long-term patency and the expense of the percutaneous transluminal angioplasty (PTA) and stentin (PTS) for central vene stenosis (CVS) in maintenance hemodialysis patients. Methods We retrospectively analyzed the patients receiving PTA or PTS in our center. Results the primary patency rates after PTA for 3, 6, 12 and 24 months were 88.2%, 73.3%, 57.1% and 37.5% respectively, and the secondary patency rates were 94.1%, 86.7%, 71.4% and 50.0% respectively. The primary patency rates after PTA+PTS for 3, 6, 12 and 24 months were 88.9%, 66.7%, 33.3% and 0% respectively, and the secondary
patency rates were 100%, 83.3%, 66.7% and 33.3% respectively. The average expense for the first PTA was 2,0938.50 yuan, and the average expense for the first PTS was 3,2599.58 yuan. Conclusion Currently, the endovascular interventional treatment for CVS is expensive. The long-term patency still depends on the development of advanced technology and devices.

Key words: Central vene stenosis, Maintenance hemodialysis, PTA, PTS